Background
==========

In palliative care, chemotherapy is as useful as watchful waiting. However, when prescribing chemotherapy for palliative treatment, an important consideration is whether chemotherapeutic agents should be administered on a daily basis. Koedoot et al reported that the patient\'s age and wishes and the expected survival gain from treatment are factors that influence the decision of therapy.\[[@B1]\] Thus, this decision represents a choice between practice and ethics, in other words, between efficacy and adverse effects.

Generally, because poor performance status (PS) is associated with poor prognosis,\[[@B2]\] oncologists are reluctant to administer chemotherapy to patients with poor PS. We describe a case of metastatic breast cancer where the Eastern Cooperative Oncology Group (ECOG) PS score was 4. The patient was treated with low-dose capecitabine, in accordance with her wishes. Despite being administered in a low dose, this chemotherapeutic agent effected a significant improvement in the patient\'s activities of daily living (ADL) and quality of life (QOL) without any severe toxicities.

Case presentation
=================

Patient characteristics and chief complaints
--------------------------------------------

The patient was a 43-year-old Asian female with metastatic breast cancer who visited our clinic after a year-long period of treatment suspension for undergoing alternative therapy. The patient presented with ulcerated lesions on the anterior chest and dyspnea due to malignant pleural effusion. Apart from the reported complaints, the patient\'s medical history was unremarkable; and so were the family and social histories.

History of present illness
--------------------------

The patient was diagnosed with invasive ductal carcinoma of the left breast (Stage IIIb) on February 2004. Pathological examination of the needle biopsy sample was performed. Immunohistochemical analysis revealed that the tumor cells were positive for estrogen receptors and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2) overexpression. The tumor was graded as intermediate (grade 2) according to the nuclear grading system. The patient was administered doxorubicin and cyclophosphamide, followed by docetaxel as neoadjuvant chemotherapy. Trastuzumab was later added to the chemotherapy regimen. However, there was recurrence of the breast cancer, for which she was treated with weekly doses of paclitaxel and trastuzumab. On April 2005, after trans-areolar total glandectomy, she was readministered trastuzumab. However, local and axillary recurrence of the tumor occurred 4 and 2 times, respectively. The tumor cells tested negative for estrogen receptors and progesterone receptors; however, HER2 overexpression persisted. She received a combination therapy of vinorelbine and trastuzumab. Thereafter, treatment from our clinic was stopped for a year since the patient wanted to undergo alternative therapy. She revisited our clinic in January 2009 for ulcerated lesions on the anterior chest and severe dyspnea. Positron-emission tomography (PET) revealed bilateral increased uptake of 18F-fluorodeoxyglucose in the metastatic lesions of the chest wall, liver, and multiple bone metastases.

Course
------

At presentation, the patient was cachexic, had edema secondary to malnutrition, and had moderate dyspnea due to malignant pleural effusion. We admitted her to a municipal hospital for 1 week her general condition improved. Intercostal tube drainage for malignant pleural effusion improved the patient\'s dyspnea. We believed that the patient could survive for 3 months after this treatment. However, she and her family were of the opinion that she be administered chemotherapy and managed at home. Therefore, we prescribed low-dose capecitabine (600 mg/day). The cycle of treatment was 3 consecutive weeks of drug administration followed by a 1-week rest period. Significant improvements after the first cycle were seen in the ulcerated lesions of the anterior chest and dyspnea, without the development of any severe adverse effects. After 2 cycles, the cutaneous lesions had resolved almost completely (Figure [1](#F1){ref-type="fig"}) and there was improvement of ADL and QOL. After 3 cycles, PET and computed tomography (CT) were performed. Tumor shrinkage was seen in the breast and liver (Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"}). Although there was recurrence of pleural effusion, the patient did not experience much discomfort and did not have symptoms such as shortness of breath. Finally, the patient discontinued capecitabine at her own discretion because of slight hair loss.

![**a) Cutaneous metastases with ulcerated lesions of breast cancer on the anterior chest wall**. b) Shrinking metastases and reduction of ulcerated lesions after chemotherapy.](1757-1626-2-9081-1){#F1}

![**a) Positron emission tomography scan shows bilateral large masses in the chest wall**. b) Decrease in tumor mass after chemotherapy.](1757-1626-2-9081-2){#F2}

![**Positron emission tomography/computed tomography fusion images show strong 18F-fluorodeoxyglucose (FDG) uptake in the region of a) the anterior chest wall and b) liver**. After chemotherapy, FDG uptake was significantly diminished in the region of c) the anterior chest wall and d) liver.](1757-1626-2-9081-3){#F3}

Discussion
==========

In palliative oncology, the relevance of chemotherapy as a palliative treatment has not been established clearly. Some studies have reported that chemotherapy as palliative treatment is effective in improving the patient\'s QOL score,\[[@B3],[@B4]\] but other studies on this topic report that there was no change in this score.\[[@B5]\]

Capecitabine, an orally administered fluoropyrimidine carbamate, has been proven to be effective for metastatic breast cancer. In particular, oral capecitabine monotherapy has been shown to improve the QOL in patients who were previously treated for metastatic breast cancer.\[[@B6]\]

Our patient was treated with low-dose (600 mg/day) capecitabine monotherapy. Silva et al.\[[@B7]\] reported the effectiveness of low-dose capecitabine (1500 mg·/m^-2^·/day) with low-dose docetaxel; however, there are no reports on the use of low-dose capecitabine monotherapy. In preliminary and phase I studies on capecitabine, no grade 3 to 4 toxicities were seen at a dose of 502 mg/·m^-2^·/day.\[[@B8],[@B9]\] In line with this result, no severe adverse effects were observed in our patient at a dose level of approximately 500 mg/m^-2^·/day. In the drug packages marketed in Japan, the package insert indicates that the standard dose of this drug is 1800 mg/day. Generally, tumor response to capecitabine treatment is not expected at low doses (e.g. 600 mg/day) of the drug. The key determinants of fluorouracil sensitivity are the enzymes thymidilate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase.\[[@B10]\]Favorable changes in the activity levels of these enzymes and some genetic factors may positively influence tumor response to the drug, and palliation may be achieved without the development of severe toxicities.

In a retrospective study of patients with cutaneous metastases, Lookingbill et al. reported that breast cancer is the commonest primary tumor in females.\[[@B11]\] There is no specific systemic chemotherapy for cutaneous metastases of breast cancer, but Sideras et al. reported that capecitabine therapy elicited significant response with resolution of cutaneous metastases.\[[@B12]\] Because wound odor and exudates result in a deterioration of the QOL, we think that chemotherapy with low-dose capecitabine as palliative treatment may provide clinically meaningful outcomes.

Conclusion
==========

This case showed low-dose capecitabine dramatically improved the patient\'s ADL and QOL. In fact, the PS score of this patient improved from 4 to 1. In palliative oncology, it is suggested that chemotherapy in the form of low-dose capecitabine monotherapy can be considered as a viable option for palliative management of metastatic breast cancer.
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